| Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10269), 99-111, 2021 | 5431 | 2021 |
| Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial PM Folegatti, KJ Ewer, PK Aley, B Angus, S Becker, ... The Lancet 396 (10249), 467-478, 2020 | 2825 | 2020 |
| Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial MN Ramasamy, AM Minassian, KJ Ewer, AL Flaxman, PM Folegatti, ... The Lancet 396 (10267), 1979-1993, 2020 | 1705 | 2020 |
| Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four … M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10277), 881-891, 2021 | 1361 | 2021 |
| T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial KJ Ewer, JR Barrett, S Belij-Rammerstorfer, H Sharpe, R Makinson, ... Nature medicine 27 (2), 270-278, 2021 | 615 | 2021 |
| Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses JR Barrett, S Belij-Rammerstorfer, C Dold, KJ Ewer, PM Folegatti, ... Nature medicine 27 (2), 279-288, 2021 | 344 | 2021 |
| Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002) A Flaxman, NG Marchevsky, D Jenkin, J Aboagye, PK Aley, B Angus, ... The Lancet 398 (10304), 981-990, 2021 | 275 | 2021 |
| Activation-induced Markers Detect Vaccine-Specific CD4+ T Cell Responses Not Measured by Assays Conventionally Used in Clinical Trials G Bowyer, T Rampling, J Powlson, R Morter, D Wright, AVS Hill, KJ Ewer Vaccines 6 (3), 50, 2018 | 81 | 2018 |
| Safety and immunogenicity of a heterologous prime-boost Ebola virus vaccine regimen in healthy adults in the United Kingdom and Senegal N Venkatraman, BP Ndiaye, G Bowyer, D Wade, S Sridhar, D Wright, ... The Journal of infectious diseases 219 (8), 1187-1197, 2019 | 69 | 2019 |
| Detecting malaria hotspots: a comparison of rapid diagnostic test, microscopy, and polymerase chain reaction P Mogeni, TN Williams, I Omedo, D Kimani, JM Ngoi, J Mwacharo, ... The Journal of infectious diseases 216 (9), 1091-1098, 2017 | 60 | 2017 |
| Phase I assessments of first-in-human administration of a novel malaria anti-sporozoite vaccine candidate, R21 in matrix-M adjuvant, in UK and Burkinabe volunteers N Venkatraman, AB Tiono, G Bowyer, J Powlson, KA Collins, S Coulibaly, ... MedRxiv, 19009282, 2019 | 19 | 2019 |
| Deep immune phenotyping and single-cell transcriptomics allow identification of circulating TRM-like cells which correlate with liver-stage immunity and vaccine-induced … A Noé, MS Datoo, A Flaxman, MA Husainy, D Jenkin, D Bellamy, ... Frontiers in Immunology 13, 795463, 2022 | 12 | 2022 |
| Safety and immunogenicity of a heterologous prime-boost Ebola virus vaccine regimen-ChAd3-EBO-Z followed by MVA-EBO-Z in healthy adults in the UK and Senegal N Venkatraman, BP Ndiaye, G Bowyer, D Wade, S Sridhar, D Wright, ... J Infect Dis 219 (8), 1187-97, 2018 | 11 | 2018 |
| High level efficacy in humans of a next-generation Plasmodium falciparum anti-sporozoite vaccine: R21 in Matrix-M (TM) adjuvant N Venkatraman, G Bowyer, NJ Edwards, O Griffiths, J Powlson, D Silman, ... 66th Annual Meeting of the American Society of Tropical Medicine and Hygiene …, 2017 | 9 | 2017 |
| Examining human paragonimiasis as a differential diagnosis to tuberculosis in The Gambia R Morter, I Adetifa, M Antonio, F Touray, BC de Jong, CM Gower, F Gehre BMC research notes 11, 1-5, 2018 | 7 | 2018 |
| Impact of exposure to malaria and nutritional status on responses to the experimental malaria vaccine ChAd63 MVA ME-TRAP in 5-17 month-old children in Burkina Faso R Morter, AB Tiono, I Nébié, O Hague, A Ouedraogo, A Diarra, NK Viebig, ... Frontiers in immunology 13, 1058227, 2022 | 6 | 2022 |
| The role of regulatory T cells in immunity to malaria RA Morter University of Oxford, 2019 | | 2019 |
| The role of regulatory T cells in the control of parasite growth and clinical outcomes following controlled human malaria infection in semi-immune Kenyan adults RA Morter, D Nyabundi, J Mwacharo, M Kapulu, D Kimani, J Ngoi, ... American Journal of Tropical Medicine and Hygiene 99 (4 supplement), 2018 | | 2018 |
| REGULATORY T CELL-MEDIATED SUPPRESSION OF HUMAN IMMUNE RESPONSES TO INVESTIGATIONAL MALARIA VACCINES RA Morter, FM Ndungu, AV Hill, P Bejon, K Ewer AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE 97 (5), 129-129, 2017 | | 2017 |
